Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. The brokerage currently has $3.50 price objective on the biotechnology company’s stock.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Other research analysts have also issued research reports about the company. HC Wainwright upped their price target on Capricor Therapeutics from $3.50 to $12.40 and gave the company a buy rating in a research report on Monday, July 15th. ValuEngine raised Capricor Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, Maxim Group reaffirmed a hold rating on shares of Capricor Therapeutics in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $6.63.

CAPR opened at $2.92 on Tuesday. The business has a 50 day simple moving average of $4.08 and a two-hundred day simple moving average of $1.71. The firm has a market capitalization of $10.92 million, a price-to-earnings ratio of -0.56 and a beta of 1.69. Capricor Therapeutics has a one year low of $2.53 and a one year high of $12.30.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.21. The business had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.22 million. Capricor Therapeutics had a negative return on equity of 270.78% and a negative net margin of 794.63%. On average, analysts anticipate that Capricor Therapeutics will post -2.87 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured Story: Death Cross

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.